CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Anebulo Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Anebulo Pharmaceuticals Inc
1017 Ranch Road 620 South, Suite 107
Phone: 737-2035270p:737-2035270 LAKEWAY, TX  78734  United States Ticker: ANEBANEB
This company ceased filing statements with the SEC on 3/2/2026.
Business Summary
Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity in children, acute cannabinoid intoxication (ACI) in adults, and the landscape of acute cannabis-induced conditions. Its lead product candidate, selonabant (formerly ANEB-001), has completed a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of ACI in healthy adults challenged with oral tetrahydrocannabinol. Selonabant is orally bioavailable, absorbed, and has also been formulated for intravenous administration. Selonabant is intended to reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also focused on the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity. Selonabant is a competitive antagonist at the human cannabinoid receptor type-1 receptor.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20256/30/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board, Founder Joseph F.Lawler 53 4/1/2020 4/1/2020
Chief Executive Officer, Director Richard A.Cunningham 55 10/6/2023 10/6/2023
Part Time Chief Financial Officer DanielGeorge 55 9/28/2023 9/28/2023
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 2 (As of 6/30/2025)
Outstanding Shares: 40,784,731 (As of 2/6/2026)
Shareholders: 15
Stock Exchange: OTC
Federal Tax Id: 851170950
Fax Number: 888-7177274


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, June 15, 2026